AI 聊天
Loading data for ALLR — first visit, this takes a few seconds.

Allarity Therapeutics, Inc.

ALLR · NasdaqCM · USD

1.26 +0.00 (0.00%)

收盤價: Sep 14, 2026, 8:00 PM

市值
$18.62M
成交量
33.5K

Allarity Therapeutics, Inc.(ALLR)股價、分析與資料

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →
營收 (ttm)
$345.0K

正在載入...

最新財報

已通報較預期YoY 變更
營收$25.00Kn/an/a
EPS-$0,21+$0,04-40.00%

下次財報

查看財報詳情 →

指標

買價
0.91
市值
18.6M
淨利(ttm)
-12.3M
0.56
-0.79
n/a
-1.21
P/B (ttm)
5.27
P/S (ttm)
53.96
財報日期
n/a
賣價
1.6
成交量
33,455
20 日平均成交量
103,443
開盤價
1.29
前收盤價
1.26
當日區間
1.23 - 1.35
52 週範圍
0.77 - 1.89
股利
n/a
除息日
n/a

關於 Allarity Therapeutics, Inc.

查看公司資料 →
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida. Biotechnology · Healthcare

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

類股 Healthcare
IPO 日期 Dec 21, 2021
員工 7
證券交易所 NasdaqCM
股票代號 ALLR